Evaluation of the Antitumor Effects of C-Myc-Max Heterodimerization Inhibitor 100258-F4 in Ovarian Cancer Cells

Journal of Translational Medicine- United Kingdom

doi 10.1186/s12967-014-0226-x

Full Text

Abstract

Available in

Date

Authors

Publisher

Springer Science and Business Media LLC

Related search

SNORD89 Promotes Stemness Phenotype of Ovarian Cancer Cells by Regulating Notch1-C-Myc Pathway

Journal of Translational Medicine
BiochemistryMedicineGeneticsMolecular Biology
2019English

Antitumor Effects and Mechanisms of Dendritic Cells Stimulated by sCD40L on Ovarian Cancer Cells in Vitro

OncoTargets and Therapy
OncologyPharmacology
2013English

Activity of the Multikinase Inhibitor Dasatinib Against Ovarian Cancer Cells

British Journal of Cancer
Cancer ResearchOncology
2009English

Preclinical Evaluation of Antitumor Activity of the Proteasome Inhibitor MLN2238 (Ixazomib) in Hepatocellular Carcinoma Cells

Cell Death and Disease
Molecular NeuroscienceImmunologyCell BiologyCancer ResearchCellularMedicine
2018English

The Myc Negative Autoregulation Mechanism Requires Myc-Max Association and Involves the C-Myc P2 Minimal Promoter.

Molecular and Cellular Biology
Cell BiologyMolecular Biology
1997English

Effects of Isoliquiritigenin on Ovarian Cancer Cells

OncoTargets and Therapy
OncologyPharmacology
2018English

Antitumor Mechanism of Gold Nanoparticles in Ovarian Cancer

Science-Business eXchange
2013English

Abnormal Expression of C-Myc Oncogene in NK Cells in Patients With Cancer

International Journal of Molecular Sciences
Organic ChemistryMolecular BiologyTheoretical ChemistryInorganic ChemistryComputer Science ApplicationsSpectroscopyMedicineCatalysisPhysical
2019English

C-Jun-Nh2-Kinase-1 Inhibition Leads to Antitumor Activity in Ovarian Cancer

Clinical Cancer Research
Cancer ResearchOncology
2009English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2026 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy